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Abstract 
 
Extended Spectrum β-lactamases (ESBLs) emerge by point mutation from non-
extended spectrum precursors . The aims of this study was to reveal the molecular 
bases of variations in resistance levels found in a collection of 21 Klebsiella pneumoniae 
clinical isolates from Brisbane, Australia and to further elucidate the natural history and 
evolution of blaSHV genes. Previous studies have shown that 13 of these isolates 
express ESBLs, blaSHV-11, blaSHV-2a and blaSHV-12 are present in these isolates,  different 
blaSHV variants co-exist in individual isolates, and that there is an association between 
the copy numbers of the ESBL encoding genes and resistance levels. In this study, a 
real-time PCR method for interrogating the polymorphic sites at codons 238 and 240 
was developed and this confirmed the relationship between mutant gene copy numbers 
and resistance levels. Analysis of multiple clones of PCR products confirmed the 
generality of the co-existence of different variants in individual isolates. The blaSHV 
promoter region was cloned from one of the ESBL expressing isolates and this showed 
that blaSHV genes exists downstream of two different promoters within this single isolate. 
These promoters have both been reported previously, and differ by virtue of the 
presence or absence of an IS26 insertion. The blaSHV copy numbers in cis with the 
different promoters were measured by real-time PCR in all isolates, and the copy 
number in cis with the IS26 promoter was correlated with resistance levels while the 
copy number of blaSHV in cis with the non-IS26 promoter was constant. Cloning and 
analysis of PCR products showed that different blaSHV variants existed in cis with 
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individual promoters in individual isolates, but that mutant genes were more abundant 
downstream of the IS26 promoter. While not all isolates possessed blaSHV in cis with the 
IS26 promoter, there were no ESBL+ isolates without this cassette.  However, not all 
isolates with this cassette were ESBL+. It was concluded that blaSHV in cis with the IS26 
promoter is located on an amplifiable replicon, and that in the absence of this cassette it 
may be difficult for these organisms to acquire an ESBL+ phenotype.  
 
 
.
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Introduction. 
 
SHV β-lactamases are prevalent in Gram-negative bacteria (2).  SHV-1 can hydrolyse 
penicillin and cephalosporins but not expanded-spectrum antibiotics such as oxyimino 
cephalosporins and monobactams.  The introduction and widespread use of expanded-
spectrum antibiotics, has led to the appearance of extended spectrum β-lactamases 
(ESBLs) which are able to hydrolyse these compounds (1).    
 
Numerous variants of the SHV enzyme have been reported 
(www.lahey.org/studies/webt.stm). Variation is exclusively in the form of amino acid 
substitutions (8, 9).  Jacoby (6) has assembled data from studies on the effects of 
substitutions on activity.  It appears that elevated SHV enzyme activity and an extended 
spectrum of activity is always seen with the G238S substitution while a further 
expansion of spectrum and increased enzyme activity is associated with the E240K 
mutation.  Although many other substitutions have been reported it appears that for the 
SHV family, the 238 and 240 sites are the most functionally important.  
 
Previously, we have reported the study of a collection of 21 K. pneumoniae isolates that 
included 13 isolates that expressed SHV ESBLs (5).  The SHV β-lactamase genes 
identified in this collection encoded SHV-1 and SHV-11 (non-ESBL), SHV-2a (ESBL 
with G238S mutation) and SHV-12 (ESBL with G238S and E240K mutations).   SHV-11, 
SHV-2a and SHV-12 differ from SHV-1, SHV-2 and SHV5 respectively at codon 35 
where there is an L35Q substitution. Limited cloning of PCR products and isoelectric 
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focusing suggested that most, if not all the isolates contain multiple SHV β-lactamase 
encoding genes. A single-base extension method for interrogating the polymorphic sites 
in codons 238 and 240 was developed, and this revealed strong correlation between the 
level of resistance to expanded-spectrum β-lactam antibiotics and the relative copy 
numbers of the different blaSHV alleles(5).   
  
The co-existence of different blaSHV alleles within individual isolates is of considerable 
practical significance because, as has been noted by others (Perilli et al, 2002), it raises 
questions about the validity of surveys in which blaSHV are amplified from genome 
extracts and the primary PCR product identified by sequencing.  Genes with both the 
codon 238 and codon 240 mutations would be expected to be dominant (as opposed to 
recessive) over single mutation or unmutated genes with respect to resistance to 
expanded spectrum β-lactams. It is easy to envisage a situation in which a mutant gene 
is in a small minority in comparison to its un-mutated homologs and yet confers the 
clinically relevant resistance phenotype. Therefore, the first part of this study was 
designed to confirm the results of the minisequencing-based allele copy number 
measurements using a newly developed real-time PCR assay for allele copy-number 
ratios, and also by carrying out extensive cloning and sequencing of blaSHV-derived PCR 
products. In the second part of this study, we characterized the blaSHV promoters, and 
investigated whether different promoters could co-exist in single isolates, whether 
homologous recombination equilibrates blaSHV across different replicons, which 
promoters are associated with copy-number variation, and whether our results are 
consistent with previous studies of the epidemiology of SHV-11,2a,12 family. In the 
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course of this work we developed a suite of real-time PCR-based methods for directly 
determining blaSHV copy numbers, and these will likely prove useful in future studies of 
the natural history of SHV ESBLs.  
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Materials and Methods. 
 
Bacterial Isolates 
 
The twenty one isolates of Klebsiella pneumoniae used in this study were isolated at the 
Princess Alexandra Hospital in Brisbane, Australia and have been previously 
characterised (5, 14).  All strains were cultured in Luria-Bertani Broth and stored in 
cryovials with 12% glycerol at –80°C. 
 
DNA extraction 
 
DNA was extracted from 2.5mL cultures grown overnight in Luria-Bertani broth.  For 
each isolate, 1mL of culture was centrifuged for 2 min at room temperature. The 
supernatant was discarded and the pellet washed twice in TE buffer (10 mM Tris, 1 mM 
EDTA, pH 8.0).  The pellet was then resuspended in  500μl TE buffer  and boiled for 20 
min.  The lysed cells were then centrifuged for 2 mins and the supernatant removed and 
stored at -20°C. 
 
Kinetic PCR interrogation of mutations in bla genes 
 
All reactions were performed using an ABI Prism 7000 real-time PCR device (Applied 
Biosystems). Allele specific PCR primers were designed to interrogate single nucleotide 
polymorphisms (SNPs) within the blaSHV gene.  PCR was performed in 96 well optical 
plates (Applied Biosystems) with a total reaction volume of 20μl.  SYBR-Green 1 2X 
master mix (Applied Biosystems) was used for all reactions with, 5 pmol common primer 
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and either 5 pmol of either the wt specific primer or mt specific primer and 1 μl bacterial 
cell lysate. The thermocycling parameters were an initial denaturation step of 95°C for 
600 sec; 40 cycles of denaturation at 94°C for 15 sec, primer annealing at 60°C for 20 
sec and extension/optical read at 72°C for 30 sec.  The point at which the fluorescence 
reaches a defined threshold defines a cycle number, called the CT value.  The threshold 
for each reaction plate was set in linear phase of amplification. 
 
The position of SNP and allele specific primers used are shown in Table 1. All primers 
were designed using Primer Express V2.0 from Applied Biosystems, and have a 
theoretical Tm of 60o C.  The codon 238 SNP was interrogated using Shv238mt and 
Shv238wt as the allele specific primers, and Shv238 reverse as the common primer. 
The codon 240 SNP was interrogated using Shv240mt and Shv240wt as the allele 
specific primers and Shv240 reverse as the common primer.  
 
Determination of sequence flanking the blaSHV gene in isolate I1 
 
A gene library of isolate I1 was constructed using λ EMBL3 Packagene system 
(Promega) in accord with manufacturer’s instructions.  Resultant plaques were 
transferred to nitrocellulose filters for screening with nucleic acid probes.  Dig labeled 
blaSHV PCR product was generated using primer set SHVF/Shv238reverse (Table1) with 
DIG labeled dNTP nucleotide mix (Roche).  Southern hybridizations using DIG labeled 
PCR product were then performed using DIG easy hyb kit, Anti-DIG antibody (Roche), 
CDP-star (Roche) according to manufacturer’s instructions.  Hybridizing plaques were 
 10
selected and lysate preparations were made by the liquid culture method (13).  
Recombinant λ DNA was isolated by a miniprep procedure according to manufacturers 
instructions.  Purified recombinant λ was restriction digested with Sal 1, BamH1, EcoR1 
and double DNA digestion with Sal1/BamH1, Sal1/EcoR1 and BamH1/EcoR1.  
Restriction digestion reactions were subject to gel electrophoresis using a 0.7% Agarose 
gel, TBE buffer, 40v for 20 hours.  Gels were then transferred to nylon membranes (13) 
and Southern blotted with blaSHV DIG labeled probe.  Restriction fragments that 
contained sequence complimentary to the blaSHV probe and were of suitable size for 
cloning and sequencing were cloned into appropriately digested pBlueScriptII.  White 
colonies were selected and grown overnight in LB amp and the recombinant plasmid 
purified by alkaline lysis plasmid miniprep procedure (13).  The recombinant plasmid 
inserts were then sequenced using primer-walking methods.  The complete insert 
sequence of assembled and compared to all known sequence using the BLASTN 
program (NCBI). 
 
Cloning and analysis of blaSHV genes and gene fragments.  
 
PCR amplicons were generated from isolates B2, K2, J3, D1, L1, A1, J2, I1 using primer 
sets that amplify all blaSHV variants (SHV-F/Shv238reverse), and primer sequences that 
amplify the 5’ end of blaSHV together with upstream flanking sequence  (pr-F/ 
Shv238reverse and pr::IS26-F/ Shv238reverse) (Table1).  Amplification products were 
cloned using the pGEM-T Easy plasmid kit (Promega) and JM109 high efficiency 
electro-competent Escherichia coli cells prepared as described by Sambrook and 
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Russell (13).  Twenty clones were selected for each strain and plasmid miniprep 
isolations were carried out for use in subsequent sequencing and real-time PCR 
interrogation analysis.  Plasmid miniprep solutions diluted 400 fold were used as 
template for real-time PCR clone screening.  Real-time PCR interrogation of clones was 
performed using the kinetic PCR method described above.    
 
Sequence determination 
 
Cloned plasmid DNA was purified using QIAquick miniprep kits (Qiagen), and plasmid 
DNA was quantified by UV spectrophotometry.  DNA plasmid (200-500ng) was 
sequenced using 3.2 pmol of appropriate primer.  Sequencing was performed at the 
Australian Genome Research Facility (AGRF), University of Queensland, Brisbane, 
Australia.   
 
Relative quantitation using real time PCR 
 
Real-time PCR was used to determine the inter-isolate relative copy numbers of total 
blaSHV and also  blaSHV in cis with different flanking sequences. The  -ΔΔCT method  
(User Bulletin 2, ABI PRISM 7000 sequence detection system; Applied Biosystems) was 
used with the 16S-RNA encoding gene as the standard.  All measurements were carried 
out in triplicate. The procedure was validated by making a 2-fold dilution of the genomic 
preparation from isolate I1 and determining that for all four primer sets the slopes of CT 
vs log dilution fell between -0.1 and +0.1.  
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While the -ΔΔCT method can be used to estimate the absolute ratio between the copy 
numbers of the same target in different isolates, it cannot be used to determine the 
absolute copy number ratio of different targets. The approach taken to estimating this 
parameter was to assume that the total amount of blaSHV in any given isolate is equal to 
the amount of blaSHV in cis with flanking sequence 1 + the amount amount of blaSHV in 
cis with flanking sequence 2 (see Results and Discussion). The relative copy number 
data from different isolates was then used to generate simultaneous equations, the 
solution of which provided an estimation of the absolute copy number ratios of the 
different targets.    
 
The primers used are shown in Table 1, and fully specified in the “Results and 
Discussion” 
 
Typing by pulsed-field gel electrophoresis (PFGE). 
 
Isolates were streaked from glycerol stocks onto Mueller Hinton II Agar and incubated at 
37°C for 24 hours.  As single colony from each isolate was then selected and grown in 
3ml of Mueller Hinton II Broth at 37°C for 20 hours with gentle agitation. The control 
strain used for PFGE experiments was K. pneumoniae ATCC13883.  DNA was 
extracted from isolates, digested with Xba I and subject to PFGE using GenePath Group 
6 Reagent Kit (Bio-rad) as per manufacturer’s instructions.    
 
Results and Discussion. 
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Interrogation of the codon 238 and 240 polymorphic sites using kinetic PCR 
The first aim of this study was to develop a single step real-time PCR method for 
interrogating the blaSHV codon 238 and 240 polymorphisms. This was done to determine 
if the minisequencing-based relative copy number determinations by Howard et al (5) 
could be confirmed, and to facilitate experiments designed to elucidate the molecular 
bases for the allele copy number variations. The approach used was allele specific real-
time PCR, which is also known as kinetic PCR (4).   This exploits the reduced extension 
frequency from a mismatched 3’ end of a PCR primer. It is more inherently robust than 
conventional, end-point analysed allele specific PCR because it depends upon a 
difference between the allele specific reactions with respect to the thermocycle number 
at which amplimer is detectable (the ΔCt), rather than a difference between the amounts 
of amplimer in the allele specific reactions at the reaction end-points.  With equal copy 
numbers of the two alleles, each amplification product should reach a detectable level at 
the same CT value. If an unequal amount of an allele is present, the difference in the 
cycle number (or ΔCT value) between the two amplification reactions provides a 
measure of relative gene dosages of each allele.   
 
All 21 isolates were subject to three real-time assays with each allele specific primer set 
and the ΔCT values and their standard deviation calculated (Table 2). It is clear that the 
isolates may be divided into distinct clusters.  There is a discontinuity in the codon 238 
results that separates the double disk synergy test (DDST) negative isolates (ΔCT <-
4.14) from the DDST positive isolates (ΔCT >-0.65).  A second discontinuity in the codon 
240 results separates the high resistance (i.e. high MIC) DDST positive isolates (ΔCT >-
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2.46) from the low resistance DDST positive and DDST negative isolates (ΔCT <-5.91).  
In the case of the high resistance isolates (L1, J2, C1, J1, G1, L1 and H1), there was a 
clear trend for the higher Δ CT values to be associated with the highest resistance, 
although the codon 240 Δ CT for isolate C1 is unexpectedly high. Despite the isolate C1 
result, the correlation coefficient for these isolates for the log MIC for aztreonam (chosen 
because of the greatest range) vs the sum of the codon 238 and codon 240 ΔCt values 
is 0.73. The results are entirely consistent with the previously reported mini-sequencing 
data (5) and conform that relationship between blaSHV-12 copy numbers and resistance 
levels.  
 
Direct determination of allele copy number ratios by analysis of cloned blaSHV PCR 
products. 
 
In order to provide additional confirmation that the kinetic PCR procedure provided a 
true indication of blaSHV allelic dosage within an isolate, we carried out cloning and 
analysis of blaSHV PCR products from isolates B2, K2, J3, A1, D1, J2, L1 and I1. blaSHV 
internal sequences spanning codons 238 and 240 were amplified from total cellular 
DNA. The amplified material was ligated to pGEM-T and transformed into E. coli JM109. 
Initially, inserts in five clones derived from each isolate in the total blaSHV PCR group 
were sequenced and also subject to the kinetic PCR assays. Both methods clearly 
identified the same bases at the codon 238 and 240 polymorphic sites, and it was 
concluded that the real-time PCR procedure was suitable for screening of more clones. 
Fifteen more clones from each isolate were analysed by this method. 
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The results of clone interrogation are shown in Table 3. These are consistent with the 
data in Table 2.  Isolate B2, K2 and J3 are DDST- and as expected possessed no 
mutant alleles. Isolate A1 is one of the lowest resistance DDST+ isolates and as 
expected had a high proportion of wild type alleles and no double mutant alleles.  Isolate 
D1 has a slightly higher level of resistance than A1, and consistent with this, a lower 
proportion of wild-type clones were recovered. Interestingly, this isolate also yielded a 
small number of double mutation clones, despite having an intermediate resistance 
phenotype. Isolate J2 is at the low resistance end of the group of isolates that have 
previously been shown to possess the double mutation. This isolate did not yield any 
clones of the single mutation allele. Rather the majority of clones were wild type and a 
substantial minority were of the double mutation allele. Although this result was 
somewhat unexpected, it is consistent both with the high resistance phenotype and also 
the significantly negative ΔCT value obtained from the interrogation of the codon 238 
mutation site. Isolate L1 has a similar resistance phenotype to J2. The distribution of 
clones is also similar, with the only differences being a slightly lower proportion of wild 
type alleles and the presence of a small number of single mutation alleles. Finally, 
isolate I1 has one of the highest resistance phenotypes. As expected, the majority of the 
clones recovered were of the double mutation allele. These data confirmed that there is 
correlation between relative allele copy numbers and resistance phenotypes. In addition 
they reveal a complex pattern of variation from isolate to isolate and suggest that 
different mixes of alleles can, on occasion, give rise to similar resistance levels.  
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Characterisation of sequences flanking blaSHV in isolate I1.  
 
To further understand the molecular basis for the co-existence of different blashv alleles, 
sequences upstream from blaSHV were cloned and characterised.  Isolate I1 was 
selected as this isolate is DDST+ and highly resistant. To avoid prejudging the nature of 
the upstream sequences, a cloning-based approach (as opposed to PCR) was used.  A 
λEMBL3 library of partially Sau3A cleaved DNA was constructed and screened by 
plaque hybridisation with a blaSHV-derived probe. Two hybridising plaques, λI1-3 and 
λI1-9, were isolated and their genomes purified. Restriction analysis revealed that the 
inserts were 22-24 kb in size. There was no discernible overlap i.e. there was no 
commonality of restriction fragments. Southern hybridisation indicated that both inserts 
carry blaSHV and confirmed that the two inserts represent different genetic environments 
for blaSHV. Hybridising fragments were subcloned and sequenced and were found to be 
identical to the two previously described blaSHV promoter regions The cloned fragment 
from I1-9 was found to contain an IS26 element insertion next to the -10 upstream 
region, as has been reported for plasmids pMPA2a and PB-10 (ref) .  The cloned 
fragment from I1-3 did not contain an IS26 element and was homologous to the 
prototype SHV-1 upstream region (ref). In the interests of clarity we have termed the two 
promoter regions in cis with blaSHV,  pr::IS26- blaSHV and pr-blaSHV.  The genomes of an 
additional additional eight hybridising phage were subject to restriction analysis, and 
they were all identical to λI1-3.  
 
Inter-isolate relative copy numbers of blashv variants 
 17
  
The results described to this point show that the level of resistance is a function of the 
gene dosage of blaSHV mutant alleles. However, given that we had found that blaSHV 
genes can exist in two different genetic environments in individual isolates, it was of 
interest to know whether the genetic environment dictates the likelihood that a blaSHV 
gene will confer a high level of resistance. Accordingly, the strategy for the remainder of 
this study was to use real-time PCR to determine the inter-isolate relative copy numbers 
of total blashv and also blashv in cis with the two different promoters, and to use cloning 
and analysis of PCR products to determine the distributions of blaSHV alleles located in 
cis with the different promoters in a subset of isolates.  
 
The real-time PCR primers used are shown in Table 1. The 16sRNA encoding genes 
were amplified using primers 16sAllBactF and 16sAllBactR. Total blaSHV was measured 
using SHVquant and SHVquantR. Pr::IS26- blaSHV was measured using pr::IS26-F S 
and prquant-R. Pr-blaSHV was measured using Pr-F and  prquant-R. 
 
In order to meaningfully measure relative copy numbers using real-time PCR, several 
normalisation steps were required. In summary,  the 16s RNA encoding gene was 
chosen as the reference point to control for variability in the genome extraction 
efficiencies, and isolate K2 was selected to be the calibrator isolate.  The quantity of 
each target in each isolate was expressed as the difference in ΔCT between the 16S 
RNA gene and the target. The inter-isolate copy number ratios were then calculated 
from the difference between these ΔCT values for the different isolates. At this point the 
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data were normalised such that the quantity of each target in the calibrator isolate was 
1. The data were then further processed to provide an approximate indication of the 
relative copy numbers between different targets within individual isolates. This was 
accomplished by solving simultaneous equations derived from the data from isolates K2 
and H1, which were chosen because they spanned a wide range of pr1-26 copy 
numbers. These equations stated that for both of these isolates, the copy number of the 
total blaSHV equalled the copy number of  pr-blaSHV + pr::IS26- blaSHV. The solution to 
these equations was that in isolate K2 there is 8.8 times as many copies of pr::IS26- 
blaSHV  than there is of pr-blaSHV. This figure was then used to normalise the copy 
numbers of the other targets in all the other isolates, and this is what is shown in Table 
4.  
 
It would be expected that pr-blaSHV copy number + pr::IS26- blaSHV copy number = total 
blaSHV copy number for all the isolates. If this were not the case, then either the copy 
number determinations did not provide meaningful results, and/or blaSHV exists in cis 
with an undiscovered flanking sequence. Therefore, the correlation between total blaSHV 
and pr-blaSHV + pr::IS26- blaSHV was determined (Figure 2). A linear relationship exists 
between these two independently determined parameters, the slope of the line 
approximates to 1 and the intercept is close to the origin. This demonstrates that the 
inter-isolate copy number variations are not experimental artifacts, and essentially rules 
out the possibility that the blaSHV gene exists with an undetected different upstream 
sequence in any of these isolates.  
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It can be seen in Table 4 that pr-blaSHV displays very little copy number variation and is 
present in all isolates, while pr::IS26- blaSHV is not universally present and displays 
considerable copy number variation. Also, the isolates with the highest resistance levels 
possessed the highest copy numbers of pr::IS26- blaSHV .  These data confirm the 
relationship between copy number and resistance levels and suggest that pr::IS26- 
blaSHV is plasmid-borne while pr-blaSHV is located either on the chromosome or on a 
plasmid with very tight copy number control. 
 
PFGE Analysis of Isolates 
 
Interpretation of DNA restriction patterns generated by PFGE was performed in 
accordance with Tenover et al. (15).  There was an apparent association between 
pulsotype A and the pr::IS26- blaSHV cassette. All except one of the non-pulsotype  
isolates (C1) were negative for this cassette while all except one of the pulsotype A 
isolates (L2) carried this cassette (Table 4).  The presence of pr::IS26- blaSHV in the 
pulsotype B isolate C1 suggests it is present on a transmissible plasmid. However, 
without more detailed analyses we cannot exclude the possibility of pr::IS26- blaSHV  
being present on different plasmids in different isolates.  
 
Direct determination of the allele copy number ratios of blaSHV genes in cis with 
the different flanking sequences.  
 
In order to determine whether homologous recombination has resulted in the blaSHV 
alleles located on different replicons being in equilibrium within individual isolates, PCR 
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products representing blaSHV  in cis with the different upstream sequences were cloned 
and analysed. A representative subset of isolates was used for this experiment and the 
results are shown in Table 5. It is clear that in all isolates,  pr-blaSHV is predominantly but 
not exclusively wild-type at codons 238 and 240, while the relative copy numbers for the 
allelic variants of pr::IS26- blaSHV vary greatly. It may therefore be concluded that the 
alleles are not in equilibrium within individual isolates, and that pr::IS26- blaSHV has the 
dominant effect on resistance phenotype, particularly in the highly resistant isolates. 
Also of interest was the finding that all sequences analysed possessed the L35Q 
substitution that differentiates SHV-1/2/5 from SHV-11/2a/12, irrespective iof they were 
derived from pr-blaSHV or pr::IS26- blaSHV.  
 
The proportions of the different alleles are consistent with the resistance phenotypes. 
The DDST- isolates B2 and K2 have very few mutant alleles, the highly resistant J2 and 
L1 have high proportions of the double mutant allele, and the other intermediate 
resistance isolates have intermediate allelic contents.  These data confirm that 
resistance levels are very much a function of the copy numbers of mutant alleles. The 
data also emphasise the generality of the coexistence of different alleles in these 
isolates, and clearly demonstrate that, despite the effects of homologous recombination,  
the probability that an individual blaSHV gene is mutated is a function of the replicon upon 
with the gene is located.  
 
An unexpected aspect of these results was the ubiquity of the unmutated pr::IS26- 
blaSHV. Such arrangements were found in both ESBL- and ESBL+ isolates. This 
observation means it is very unlikely that a single plasmid with a mutated blaSHV was 
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introduced into South-East Queensland or the Princess Alexandra Hospital, and then 
underwent a dissemination process. Rather, the simplest explanation is that a plasmid 
containing blaSHV-11 was extant, and mutated derivatives of this were selected on one or 
more occasions. If this is the case, then the low proportion of mutant alleles of  pr- 
blaSHV, since it suggests that if an isolate has both pr::IS26- blaSHV and pr- blaSHV and is 
subject to selection for ESBL expression, then mutations in pr::IS26- blaSHV are more 
likely to be evolutionarily fixed than mutations in pr- blaSHV.. A possible explanation for 
this is that a multicopy plasmid location and/or the presence of IS26 in the promoter 
increase expression, and thus increase the impact upon resistance phenotype of the 
mutations that confer ESBL activity. It is consistent with this hypothesis that all of the 
ESBL+ isolates in this study possessed pr::IS26- blaSHV.   
 
Our results are similar to findings from studies on the distribution and genetics of SHV-
2a and SHV-12 in Korea (Kim et al, 2002, Kim et al, 1998).  These enzymes are the 
dominant ESBL SHV variants found in that country, and it appears that their genes 
invariably possess the promoter with the IS26 insertion (Kim et al, 2002). These authors 
suggested that the SHV-2a and SHV-12 enzymes arose from an SHV-11 precursor 
whose gene also possessed the promoter with the IS26 insertion. Our study has 
provided direct evidence in support of this model because we have detected blaSHV-11 in 
cis with the IS26 promoter, and shown it is present in both ESBL+ and ESBL- isolates. 
However, the isolate-to-isolate variations in copy number of blaSHV-11 in cis with the IS26 
promoter do not support the conjecture of Kim et al (2002) that the blaSHV-11 is 
chromosomally located and distinct from the plasmid located blaSHV-2a and blaSHV-12. 
Enterobacteriaceae expressing SHV-12 have also been found to be very widespread in 
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Italy (Perilli et al, 2002). It would be most interesting to determine if instances of wide 
dissemination of SHV-12 are always associated with IS26 insertions in the promoter.  
 
Kim et al (2002) also postulated that the acquisition of the point mutation that confers 
the L35Q substitution that defines SHV-11, SHV-2a and SHV-12 was coincident with the 
acquisition of the IS26 insertion in the promoter.  Our study has demonstrated that this is 
not the case, as all cloned PCR products that were fully sequenced contained the 
mutation, irrespective of whether there was an IS26 insertion in the promoter.  
 
In conclusion, we have used a detailed study of small collection of geographically and 
temporally linked K. pneumoniae clinical isolates to illuminate aspects of the natural 
history of blaSHV genes.  This has revealed that a mix of alleles in individual isolates is 
the norm rather than the exception, and that there is a strong relationship between high 
levels of resistance and a high copy number of blaSHV-12 .The most likely mechanism for 
the acquisition of resistance in this collection is the dissemination of a plasmid carrying 
blaSHV-11 followed by one or more rounds of selection for the ESBL+ mutants. The 
apparent ability of a gene cassette consisting of IS26 and blaSHV-11  to facilitate the 
appearance of resistance in response to selection, even in the presence of a blaSHV 
gene with a different promoter, may be of clinical significance.  We are currently 
investigating the relationship between the presence of this cassette and frequencies of 
mutation to an ESBL+ phenotype.  
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Figure Legends 
 
Figure 1.  Representation of the blaSHV upstream flanking regions for pr::IS26- blaSHV (A) 
and pr-blaSHV (B) cassettes.  Expanded nucleotide sequences in the 5` upstream region 
of cassettes is shown with homology between region defined by dotted line. The 
pr::IS26- blaSHV cassette contains the IS26 element inserted next to the -10 region (ref). 
The pr-blaSHV cassette does not contain IS26 element and is homologous to prototype 
SHV-1 upstream region (ref). 
 
Figure 2.  Linear regression analysis for blashv relative quantitation measurements. 
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CCGGCCTTTGAATGGGTTCATGTGCAGCTCCATCAGCAAAAGGGGATGATAAGTTTATCACCACCGACTATTTGCAACAGTGCCAACGCCGGCGCCGGGTTATTCTTATTTGTCGCTTCTTTACTCGCCTTTATCGGCCTTCACTCAAGGATGTATTGTGGTTATG 
TTAGGCAGGGCTAGATATTGATTATTCGAAATAAAAGATGAAAAATGATGAAGGAAAAAAGAGGAATTGTGAATCCAGCAAAACGCCGGCGCCGGGTTATTCTTATTTGTCGCTTCTTTACTCGCCTTTATCGGCCTTCACTCAAGGATGTATTGTGGTTATG 
IS26-IRL 
-35 
blaSHV 11, 2a, 12
Tnp26L Start -10
-35 
blaSHV 1, 2, 12
-10 
CAA
CTA
Codon 35
Codon 35
Codon 238 & 240
Codon 238 & 240
A. pr::IS26- blaSHV  
KpnBridgeF Primer  
SflexBridgeF Primer 
Start Codon
B. pr-blaSHV 
= 100bp 
Start Codon 
Fig 1.   
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 Table 1.  Primers for kinetic and relative quantitation PCR,  3` terminal bases for allele 
specific oligos are denoted by bold type and underlined. 
 
Primer Name Gene  Annealing 
Region 
Primer Sequence 5`-3` 
16sAllBactF 16s 
rRNA  
(+) 
1297/1318
TCCATGAAGTCGGAATCGCTAG 
16sAllBactR 16s 
rRNA  
(-)  
1374/1392
CACTCCCATGGTGTGACGG 
SHV-F blaSHV  (+)  
310/327 
TCAGCGAAAAACACCTTG 
Pr-F pNSF-1# (+) -107/-
82 
GATGAAGGAAAAAAGAGGAATTGTGA 
SHVquantF blaSHV (+)  
730/748 
TGCTTGGCCCGAATAACAA 
SHVquantR blaSHV (-)  
766/786 
GCGTATCCCGCAGATAAATCA 
Pr::IS26-F pMPA2a* (+) -158/-
141 
CCGGCCTTTGAATGGGTT 
Prquant- blaSHV (-)  -3/24 TAATACACAGGCGAATATAACGCATAAC
Shv238mt blaSHV (+)  
680/699 
CGCCGATAAGACCGGAGCTA 
Shv238wt blaSHV (+)  
680/699 
CGCCGATAAGACCGGAGCTG 
Shv238reverse blaSHV (-)  
770/781 
CGGCGTATCCCGCAGATAA 
Shv240mt blaSHV (-)  
702/716 
GCGCGCACCCCGCTT 
Shv240wt blaSHV (-)  
702/716 
GCGCGCACCCCGCTC 
Shv240reverse blaSHV (+)  
663/679 
CCGGCGGGCTGGTTTAT 
Shv35mt blaSHV (+) 70/91 AGCCGCTTGAGCAAATTAAACA 
Shv35wt blaSHV (+) 70/91 AGCCGCTTGAGCAAATTAAACT 
Shv35reverse blaSHV (-) 
174/194 
CATCATGGGAAAGCGTTCATC 
   
# Genbank Accession No: AF282921, as reported by Fortineau et al. 
* Genbank Accession No: X84314, as reported by Nuesch-Inderbinen et al. 
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(these references suck and I am going to search for the original reference 
reporting these sequences).
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Table 2.  Kinetic PCR results include one replicate of CT mt and CT wt data from each 
isolate; the average delta CT of replicates and associated delta Ct interval of standard  
deviation. The phenotypic data consisting of double disk synergy test (DDST) and 
minimum inhibitory concentration (MIC) are from Schooneveldt et al (1998) and the 
isolate designations are as in Howard et al (2002).   
 
 
Phenotypic data Kinetic PCR at codon 238 Kinetic PCR at codon 240 
MIC values (μg/ml) Isolate DDS
T ATM CAZ CTX 
CT mt
CT 
wt Δ CT SD CT mt 
CT 
wt Δ CT SD 
B2 - 0.03 0.13 0.03 22.0 16.0 -4.9 1.22 25.1 17.7 -6.6 0.82 
K2 -  0.03 0.13 0.03 21.7 14.5 -7.0 0.33 23.8 13.1 -10.4 0.55 
M1 - 0.03 0.13 0.03 24.1 18.2 -6.8 0.71 28.7 20.1 -7.3 2.67 
K1 - 0.06 0.50 0.06 21.8 15.1 -6.7 0.27 24.1 17.8 -5.9 0.52 
J5 - 0.06 0.50 0.13 24.6 16.1 -8.0 1.68 22.3 13.1 -9.1 0.39 
J3 - 0.13 0.50 0.13 22.6 17.5 -4.1 1.16 21.0 14.4 -6.5 0.78 
L2 - 0.13 0.25 0.25 26.4 17.2 -8.3 1.30 24.1 15.0 -8.5 1.01 
J4 - 0.25 2.00 0.13 21.0 15.1 -6.0 0.25 21.3 11.7 -9.3 0.31 
F2 + 0.25 0.5 0.5 16.4 17.9 1.3 0.50 24.7 13.6 -10.6 0.75 
A1 + 0.5 1 1 15.2 16.7 1.4 0.31 23.3 12.9 -10.0 0.58 
E1 + 0.5 1 1 15.9 19.2 2.2 1.23 24.8 13.7 -9.7 1.39 
B1 + 1 1 1 16.3 17.8 1.3 0.20 23.1 14.1 -8.8 0.42 
F1 + 1 1 1 15.2 16.6 1.4 0.28 22.0 13.3 -9.0 0.76 
D1 + 2 4 4 14.2 17.0 2.9 0.71 22.4 12.5 -9.8 1.05 
L1 + 32 32 1 15.3 16.4 1.5 0.46 15.0 13.7 -0.9 0.43 
J2 + 64 32 2 15.9 16.0 0.2 0.38 14.7 13.0 -1.8 0.49 
C1 + 64 64 4 16.1 16.0 -0.7 0.48 14.9 18.4 4.1 0.68 
J1 + 64 32 4 16.6 16.4 -0.2 0.22 15.5 14.0 -2.5 1.48 
G1 + 128 128 16 12.9 15.2 2.7 0.37 11.7 14.5 2.8 0.19 
I1 + 128 128 16 13.0 15.4 2.3 0.59 11.7 14.7 3.4 0.28 
H1 + 128 128 128 11.6 14.3 2.7 0.47 10.6 14.8 3.9 0.45 
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 Table 3.  Frequencies of G238S and E240K mutations as determined by cloning of 
blaSHV PCR products in isolates representing each cluster in Table 2. 
 
 
blaSHV 
Isolate Nil 
G238S 
E240K
G238S
G238S 
+ 
E240K
B2 100% - - 
K2 100% - - 
J3 100% - - 
D1 25% 65% 10% 
L1 60% 5% 35% 
A1 50% 50% - 
J2 80% - 20% 
I1 10% 25% 65% 
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 Table 4.  Relative quantitation of total cellular blaSHV ;putative replicons containing 
blaSHV and PFGE interpretations using Tenover et al criterion (15).  
 
Isolate DDST ATM CAZ CTX blaSHV 
pr::IS26- 
blaSHV 
pr-blaSHV 
Pulsotype 
B2 - 0.03 0.13 0.03 0.396 
0.356-
0.440 
NIL 0.082 
0.075-
0.090 
D 
K2 - 0.03 0.13 0.03 1.00 
0.929-
1.076 
0.897 
0.783-
1.028 
0.102 
0.089-
0.117 
A 
M1 - 0.03 0.13 0.03 0.444 
0.360-
0.548 
NIL 0.128 
0.102-
0.161 
C 
K1 - 0.06 0.5 0.06 0.331 
0.302-
0.363 
NIL 0.178 
0.150-
0.211 
B 
J5 - 0.06 0.5 0.13 0.696 
0.627-
0.773 
0.417 
0.395-
0.441 
0.175 
0.163-
0.188 
A4 
J3 - 0.13 0.5 0.13 0.289 
0.258-
0.324 
NIL 0.197 
0.161-
0.242 
A2 
L2 - 0.13 0.25 0.25 0.395 
0.303-
0.515 
NIL 0.124 
0.101-
1.53 
A5 
J4 - 0.25 2 0.13 1.875 
1.657-
2.122 
1.986 
1.642-
2.402 
0.072 
0.053-
0.96 
A2 
F2 + 0.25 0.5 0.5 0.785 
0.643-
0.958 
0.313 
0.294-
0.332 
0.099 
0.094-
0.105 
A 
A1 + 0.5 1 1 0.794 
0.716-
0.879 
0.433 
0.391-
0.480 
0.189 
0.160-
0.224 
A 
E1 + 0.5 1 1 0.664 
0.570-
0.774 
0.613 
0.503-
0.746 
0.197 
0.138-
0.282 
A6 
B1 + 1 1 1 0.655 
0.547-
0.427 
0.384-
0.150 
0.132-
A5 
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0.785 0.475 0.172 
F1 + 1 1 1 0.707 
0.661-
0.757 
0.369 
0.307-
0.445 
0.084 
0.068-
0.105 
A 
D1 + 2 4 4 1.701 
1.556-
1.860 
1.721 
1.490-
1.987 
0.085 
0.069-
0.104 
A1 
L1 + 32 32 1 0.809 
0.689-
0.949 
0.319 
0.254-
0.400 
0.087 
0.079-
0.096 
A 
J2 + 64 32 2 1.692 
1.552-
1.848 
1.277 
1.064-
1.533 
0.060 
0.018-
0.206 
A5 
C1 + 64 64 4 0.835 
0.752-
0.927 
0.613 
0.508-
0.739 
0.133 
0.114-
0.155 
B 
J1 + 64 32 4 0.968 
0.793-
1.182 
1.32 
1.16-1.51 
0.124 
0.092-
0.167 
A3 
G1 + 128 128 16 2.955 
2.498-
3.496 
3.854 
3.418-
4.347 
0.158 
0.122-
0.206 
A 
I1 + 128 128 16 4.616 
4.203-
5.070 
5.241 
4.863-
5.648 
0.093 
0.086-
0.102 
A 
H1 + 128 128 128 8.244 
7.628-
8.909 
8.111 
6.776-
9.709 
0.124 
0.102-
0.150 
A1 
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Table 5.  Frequencies of G238S and E240K mutations as determined by cloning of 
pr::IS26- blaSHV and pr-blaSHV PCR products representing each cluster and isolates of 
interest in Table 4. 
 
pr::IS26- blaSHV pr-blaSHV 
Isolate 
35-L 35-Q 
238-
G 
240-
E 
238-
S 
240-
E 
238-
S 
240-
K 
35-L 35-Q 
238-
G 
240-
E 
238-
S 
240-
E 
238-
S 
240-
K 
B2 - 100% - - - - 100% 95% 5% - 
K2 - 100% 100% - - - 100% 100% - - 
J3 - 100% - 55% 45% - 100% 95% 5% - 
D1 - 100% 5% 90% 5% - 100% 95% 5% - 
L1 - 100% 5% - 95% - 100% 95% 5% - 
A1 - 100% - 100% - - 100% 95% 5% - 
J2 - 100% 70% - 30% - 100% 100% - - 
I1 - 100% 0% 5% 95% - 100% 85% 15% - 
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